User:Mr. Ibrahem/Pertuzumab/trastuzumab/hyaluronidase

Pertuzumab/trastuzumab/hyaluronidase, sold under the brand name Phesgo, is a combination medication used to treat HER2-positive breast cancer. It contains pertuzumab, trastuzumab, and hyaluronidase (vorhyaluronidase alfa). It is injected under the skin.

Common side effects include hair loss, nausea, diarrhea, low red blood cells, weakness, and joint pain. Other side effect may include low white blood cells, infection, and heart failure. Use during pregnancy may harm the baby. Pertuzumab and trastuzumab are monoclonal antibodies which bind HER2 blocking signals for the cancer to grow. Hyaluronidase is an enzyme that improve absorption of the other medication.

The combination was approved for medical use in the United States and Europe in 2020. In the United Kingdom the first dose costs the NHS about £6,000 with subsequent doses being £3,600 as of 2021. In the United States this costs about 13,300 USD and 8,900 USD respectively.